Drug Patent Watch

OCTOBER 28, 2024

The pharmaceutical industry relies heavily on Contract Development and Manufacturing Organizations (CDMOs) to streamline the drug development and manufacturing process. Here are the top 10 CDMO services you might not have known you needed… Source

Pharmaceutical Companies

Drug Patent Watch

DECEMBER 12, 2024

Identifying branded drugs with a low likelihood of generic entry has become a crucial strategy for companies looking to expand their product portfolio through in-licensing. This approach not only helps maintain market exclusivity but also ensures a steady revenue stream for pharmaceutical companies.

Licensing

Drug Patent Watch

DECEMBER 9, 2024

This approach has led to the discovery of numerous potential drug candidates. From Lab to Market: The Long Road of Drug Development Once a promising compound is identified, it enters the long and costly process of drug development. Q: How long does a drug patent last?

Drugs

Drug Patent Watch

FEBRUARY 13, 2025

The Unsung Heroes of Generic Drug Development: The Power of Partnerships As we navigate the complex landscape of pharmaceuticals, it's easy to overlook the crucial role that partnerships play in bringing affordable, life-saving medications to market. When it comes to developing generic drugs, partnerships can take many forms.

Drug Development

Drug Target Review

DECEMBER 11, 2024

This issue poses a significant hurdle for drug developers, with no universal protocol currently in place to address these complexities. For small- and medium-sized pharmaceutical companies, outsourcing represents a strategic leap forward, offering a gateway to unparalleled expertise and cutting-edge analytical technologies.

International

Alta Sciences

JUNE 6, 2025

For a contract research organization (CRO), it can play an integral role in increasing the quality and speed of drug development while reducing costs, repetitive manual tasks, and human error. This can result in failed runs and wasted reagents.

Pharmacokinetics

Alta Sciences

JULY 3, 2025

Altasciences At CPHI Americas 2025 pmjackson Thu, 07/03/2025 - 13:41 In the ever-changing drug development world, staying agile is essential to enabling more informed decisions, faster. It’s a challenge that affects a large percentage of new drug candidates—one we’re passionate about helping to solve.

Small Molecule

SugarCone Biotech

JUNE 19, 2025

Finally, while there are clear front runners among the pharmaceutical companies developing targeted therapeutics for these antigens there are also emerging biotechs aggressively pursuing these targets. The Next Wave: Targeting B7H3 – a drug development tsunami in the making? An awesome space to watch. Stay tuned.

Therapies

Drug Patent Watch

APRIL 14, 2025

"Compliance in Generic Drug Development: A Critical Component of Success As the generic drug industry continues to grow, ensuring compliance with regulatory requirements has become a top priority for pharmaceutical companies.

Compliance

The Pharma Data

JUNE 13, 2025

The main objective of MEDISO is to aid Japanese drug-discovery ventures in navigating the complex path toward commercial readiness. This includes assistance in intellectual property strategy, securing funding, developing business plans, and preparing for eventual collaboration with large pharmaceutical companies or investors.

Research

SugarCone Biotech

JUNE 27, 2025

Finally, while there are clear front runners among the pharmaceutical companies developing targeted therapeutics for these antigens there are also emerging biotechs aggressively pursuing these targets. ADC: Antibody-Drug Conjugates First it is important to put this wave of drug development into perspective.

Therapies

DrugBank

JUNE 18, 2025

Drug development is a complex and highly regulated process. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other global counterparts, set rigorous standards to ensure that drugs are safe, effective, and high-quality. Regulatory agencies, such as the U.S.

Drug Development

Drug Target Review

MARCH 4, 2025

The MyPhenome test has already gained traction among obesity specialists, particularly in Chicago and Florida, and Phenomix has formed strategic partnerships with multiple pharmaceutical companies to support clinical trials and further analyse obesity-related data.

Therapies

Drug Target Review

JULY 14, 2025

The pharmaceutical industry faces a persistent challenge: despite significant investments in drug development, a substantial proportion of promising candidates fail due to unforeseen toxicity issues.

Drugs

Drug Target Review

JUNE 18, 2025

He works closely with pharmaceutical teams in Europe and North America to help them move faster, think differently and adapt without compromising on quality or compliance. His experience with early-stage drug developers makes one thing clear: traditional approaches to timelines, team structure and risk no longer stand up to today’s demands.

Drugs

Codon

NOVEMBER 3, 2024

As an undergraduate biology student, I spent some time in a TB lab working on antibiotic resistance — a growing concern for drug developers. The drug didn’t cure the animals at such low doses, but their health did improve, hinting at the drug’s efficacy. However, hope prevails.

Vaccine

ACTO

DECEMBER 17, 2024

Yet, the critical question remains: How can pharmaceutical companies ensure responsible and compliant AI implementation while maximizing its potential for field teams? Such cross-functional collaboration ensures consistent implementation from drug development through commercialization.

Government

Drug Patent Watch

DECEMBER 17, 2024

The Evolving Role of CDMOs in the Pharmaceutical Industry Gone are the days when CDMOs were mere service providers. Today, they’re strategic partners in drug development and manufacturing, offering end-to-end solutions that can make or break a pharmaceutical company’s success.

Pharmaceuticals

BioPharma Drive: Drug Pricing

JUNE 11, 2025

billion buyout of Blueprint Medicines is the sector’s second-largest M&A deal this year and represents the highest value paid for an immune drug developer since April 2023. Sanofi’s $9.1 Sanofi’s $9.1

FDA

SugarCone Biotech

JULY 6, 2025

Finally, while there are clear front runners among the pharmaceutical companies developing targeted therapeutics for these antigens there are also emerging biotechs aggressively pursuing these targets. This is an active drug development landscape with a lot of recent news. regulatory application in NSCLC.

Drug Development

Drug Target Review

MAY 26, 2025

In his role, he provides both strategic and technical guidance to Solvias, a global Contract Research Organisation (CRO) that offers critical analytical services to the pharmaceutical industry. Harnessing emerging technologies The rapid pace of technological innovation is reshaping the landscape of drug discovery.

Drug Development

The Premier Consulting Blog

DECEMBER 16, 2024

New drug development is a long and expensive process that can be fraught with obstacles, including unexpected delays, poor efficacy results, safety issues, or regulatory challenges. The need for difficult decisions The latest estimates on the median cost of bringing a new drug to market is now $2.3

Pharmacokinetics

BioPharma Drive: Drug Pricing

JULY 10, 2025

Editors picks George Frey/Reuters Deep Dive A decade of cancer immunotherapy: Keytruda, Opdivo and the drugs that changed oncology Over the past 10 years, PD1-blocking medicines have transformed cancer care. 4, 2024 Adeline Kon / BioPharma Dive/BioPharma Dive Deep Dive // Patent thickets Drug patents protect pharma profits.

Drugs

Drug Patent Watch

JANUARY 14, 2025

.”[2] This study not only addressed the ATA’s concerns but also highlighted the power of real-world evidence in generic drug development and regulation. Case Study 3: Modeling the Future of Generic Drugs Who says you need a crystal ball to predict the future?

Drug Development

Drug Patent Watch

DECEMBER 10, 2024

They can help ensure that these submissions are complete, accurate, and timely, which is critical for advancing drug development programs. They can help ensure that the commercial pharmaceutical manufacturing process is designed to meet regulatory requirements and offer insight into the most effective manufacturing strategies.

Compliance

BioPharma Drive: Drug Pricing

JULY 9, 2025

Editors picks George Frey/Reuters Deep Dive A decade of cancer immunotherapy: Keytruda, Opdivo and the drugs that changed oncology Over the past 10 years, PD1-blocking medicines have transformed cancer care. By Jonathan Gardner • Sept. By Jonathan Gardner • Sept.

Clinical Trials

BioPharma Drive: Drug Pricing

JULY 14, 2025

XH4D via Getty Images A group of private equity firms are pouring funding into PCI Pharma Services, betting the contract drug development and manufacturing organization’s business is poised to grow in the years ahead. By Jonathan Gardner • Sept. 4, 2024 Keep up with the story. By Jonathan Gardner • Sept.

Production

Drug Patent Watch

MARCH 10, 2025

The Future of Generic Drugs: How Technology is Revolutionizing the Industry As we continue to navigate the ever-changing landscape of healthcare, one thing is clear: technology is playing an increasingly important role in shaping the future of generic drug development. Will we see a surge in new treatments and medications?

Drug Development

Drug Patent Watch

DECEMBER 18, 2024

This exclusivity is the lifeblood of pharmaceutical innovation, allowing companies to recoup their massive R&D investments and incentivizing further research. According to a 2021 study by the Tufts Center for the Study of Drug Development, the average cost to develop a new drug is a staggering $2.6

Pharmaceuticals

The Pharma Data

JUNE 6, 2025

The Strategic Role of CSOs in a Changing Pharmaceutical Landscape Pharmaceutical contract sales outsourcing is no longer viewed as a temporary or stop-gap measure. Contract sales outsourcing is no longer just a tactical solution—it is a core element of modern pharmaceutical commercialization strategy.

Pharmaceutical Companies

Codon

JULY 14, 2025

Drugs developed in Eichengrün’s laboratory were tested at Bayer’s pharmacological laboratory, led by Heinrich Dreser. However, in 1928, the pharmaceutical company manufacturing digoxin invented “ Mother Hutton ” as part of a marketing campaign.

Treatment

Drug Patent Watch

MARCH 18, 2025

This is where generic drug development comes in a game-changer for millions of people around the world. The Growing Importance of Generic Drug Development As the global demand for affordable medications continues to rise, the importance of generic drug development cannot be overstated.

Drug Development

The Pharma Data

JUNE 24, 2025

Food and Drug Administration (FDA). Importantly, assistance provided through the fund is entirely independent of pharmaceutical companies’ product promotion strategies. Patients who receive support are not directed toward any particular therapy or drug manufacturer.

Treatment

The Pharma Data

AUGUST 1, 2025

In 2015, it became the first publicly traded biotech or pharmaceutical company to adopt Public Benefit Corporation (PBC) status. Rothblatt—an advocate of ethical biotechnology and futurist innovation—the company maintains a rare blend of financial discipline and visionary outlook.

Government

Drug Patent Watch

NOVEMBER 19, 2024

The pharmaceutical industry is undergoing significant transformations, particularly in the realm of generic drug development. Recent trends and advancements in technology, research, and collaboration are reshaping the landscape of generic drug development, leading to new opportunities and challenges for pharmaceutical companies.

Drug Development

Broad Institute

DECEMBER 18, 2023

Brain disorders are difficult to study and many drug candidates have failed in clinical trials, causing pharmaceutical companies to reduce their investments or even exit the field entirely.

Drug Development

DrugBank

OCTOBER 17, 2024

Data science has emerged as an innovative tool in the biopharmaceutical industry, leveraging the power of machine learning and artificial intelligence to drive innovation and efficiency across the entire drug development lifecycle. This was seen in the case of the BRAF V600E mutation test for melanoma patients receiving vemurafenib.

Drug Development